Form 144 CG ONCOLOGY For: 30 July
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
CG Oncology Inc (CGON)
CG Oncology Inc stock price live, this page displays NASDAQ CGON stock exchange data. View the CGON premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the CG Oncology Inc real time stock price chart below.
What Is the CG Oncology Inc Stock Price Today?
The CG Oncology Inc stock price today is 71.19.
What Is the Stock Symbol for CG Oncology Inc?
The stock symbol for CG Oncology Inc is "CGON."
What Stock Exchange Does CG Oncology Inc Trade On?
CG Oncology Inc is listed and trades on the NASDAQ stock exchange.
Is CG Oncology Inc a Good Stock to Buy?
Determining whether CG Oncology Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CGON quote. (ISIN: US1569441009)
What Is the CG Oncology Inc Stock Price Today?
The CG Oncology Inc stock price today is 71.19.
What Is the Stock Symbol for CG Oncology Inc?
The stock symbol for CG Oncology Inc is "CGON."
What Stock Exchange Does CG Oncology Inc Trade On?
CG Oncology Inc is listed and trades on the NASDAQ stock exchange.
Is CG Oncology Inc a Good Stock to Buy?
Determining whether CG Oncology Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CGON quote. (ISIN: US1569441009)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
69.60
72.94
52 wk Range
23.65
77.00
Earnings results expected in 5 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
69.6072.94
52 wk Range
23.6577.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CGON Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
90.69
Upside
+27.39%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
6 analysts have revised their earnings downwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy
Analyst Ratings
14 Buy
1 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 90.69
(+27.39% Upside)
CG Oncology Inc SWOT Analysis
Creto's Promise | Explore CG Oncology's lead asset Creto, showing promising efficacy in non-muscle invasive bladder cancer treatment with extended response duration |
Market Race | Delve into the competitive landscape as CG Oncology and Johnson & Johnson vie for dominance in the NMIBC market with innovative therapies |
Financial Fortitude | Learn about CG Oncology's robust financial position, with $550 million in cash reserves supporting ongoing development and potential commercialization |
Future Catalysts | Discover upcoming milestones, including crucial data presentations and regulatory submissions, that could significantly impact CG Oncology's market valuation |
Earnings
Latest Release
May 08, 2026
EPS / Forecast
-0.71 / -0.60
Revenue / Forecast
1.08M / --
Compare CGON to Peers and Sector
Metrics to compare | CGON | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCGONPeersSector | |
|---|---|---|---|---|
P/E Ratio | −33.6x | −8.8x | −0.3x | |
PEG Ratio | 0.61 | −0.21 | 0.00 | |
Price/Book | 5.8x | 4.1x | 2.6x | |
Price / LTM Sales | 1,238.2x | 21.7x | 3.0x | |
Upside (Analyst Target) | 26.4% | 84.4% | 56.3% | |
Fair Value Upside | Unlock | −8.2% | 9.2% | Unlock |
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the CG Oncology (CGON) Stock Price Today?
The CG Oncology stock price today is 71.19 USD.
What Stock Exchange Does CG Oncology Trade On?
CG Oncology is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for CG Oncology?
The stock symbol for CG Oncology is "CGON."
What Is the CG Oncology Market Cap?
As of today, CG Oncology market cap is 6.28B USD.
What Is CG Oncology's Earnings Per Share (TTM)?
The CG Oncology EPS (TTM) is -2.35.
When Is the Next CG Oncology Earnings Date?
CG Oncology will release its next earnings report on Aug 07, 2026.
From a Technical Analysis Perspective, Is CGON a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has CG Oncology Stock Split?
CG Oncology has split 0 times.
How Many Employees Does CG Oncology Have?
CG Oncology has 142 employees.
What is the current trading status of CG Oncology (CGON)?
As of Aug 02, 2026, CG Oncology (CGON) is trading at a price of 71.19 USD, with a previous close of 73.03 USD. The stock has fluctuated within a day range of 69.60 USD to 72.94 USD, while its 52-week range spans from 23.65 USD to 77.00 USD.
What Is CG Oncology (CGON) Price Target According to Analysts?
The average 12-month price target for CG Oncology is 90.69 USD, with a high estimate of 108 USD and a low estimate of 80 USD. 14 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +27.39% Upside potential.
What Is the CGON Premarket Price?
CGON's last pre-market stock price is 72.95 USD. The pre-market share volume is 4,150.00, and the stock has decreased by -0.08, or -0.11%.
What Is the CGON After Hours Price?
CGON's last after hours stock price is 72.00 USD, the stock has decreased by 0.81, or 1.14%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.